Scientists glue two proteins together, driving cancer cells to self-destruct

Perceived Novelty and Mechanism

• Many see the work as a clever “induced proximity” / molecular-glue approach: using a cancer-survival protein (BCL6) as a guide to bring in machinery that flips its targets from survival to cell death.
• Others note apoptosis-based cancer therapies are not new (e.g., BCL‑2 inhibitors like Venetoclax), and that the key novelty is this specific, programmable mechanism and its potential generalizability to “undruggable” targets.

Promises and Unknowns

• Commenters highlight that this could open a broad class of drugs, similar to PROTAC/targeted degradation but acting via gene-expression machinery.
• Side effects are currently speculative: possibilities raised include immune overactivation and tumor lysis syndrome if cancer cells die too quickly.

Hype, Timelines, and Real-World Impact

• Strong cynicism about headlines like “self-destruct” and “cure,” seen as medical clickbait driven by PR and journalism incentives.
• Multiple comments stress that going from cell or mouse results to approved drugs routinely takes a decade+.

Evidence of Progress vs. Stagnation

• Several participants argue cancer and other diseases have seen major advances: better survival for many cancers, immunotherapies, mRNA cancer vaccines in trials, HIV and Hep C becoming manageable/curable, MS and myeloma turning into chronic conditions.
• Others respond that many metastatic cancers remain almost as lethal, Alzheimer’s has seen little clear progress, and some big research programs (e.g., amyloid focus) may have been misdirected.

Diagnostics and Delivery Challenges

• Frustration that “we know how to kill cells” but still struggle with reliable, targeted delivery.
• This work is framed by some as precisely a targeted delivery strategy, exploiting malfunctioning gene programs.
• Future diagnostics like hyperpolarized MRI contrast agents and biomarker-monitoring toilets are discussed as crucial for earlier detection.

Alternative Therapies and Anecdotes

• Fasting, ketogenic diets, and botanical compounds (e.g., Sanguinaria) are cited anecdotally as helpful or even transformative.
• Other commenters push back, emphasizing anecdote vs. trial data and warning about unproven or disproven cancer treatments.

Regulation, Incentives, and Pharma Skepticism

• One thread blames the FDA for slowing access; others counter with expanded/compassionate use programs and the need to protect patients from ineffective or harmful treatments and fake drugs.
• There is debate over whether profit motives favor chronic treatments over cures; critics raise “sickness industry” concerns, while others argue that effective cures still earn enormous profits and would be pursued.

Human Experiences and Emotional Context

• Multiple people share recent losses or ongoing battles with cancer (including aggressive breast cancer, sarcoma, pancreatic cancer), describing shock, grief, “why me?” feelings, and the huge difference between 5 and 15 extra years.
• Philosophical and religious reflections on mortality, “memento mori,” and focusing on quality of remaining life appear alongside the technical discussion.

Meta Discussion (Reporting and Access)

• Calls for clearer labeling of research stage (cell, mouse, phase I, etc.) in headlines to curb false hope.
• Notes on Sci-Hub being blocked in some countries and on earlier related coverage of the group’s prior work.